Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007342
Chunk: 118

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 118
---
 distribution
from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security which is the subject of the distribution
until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a
security in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities offered
by this prospectus.

This offering will terminate
on the date that all of our Depositary Shares offered by this prospectus have been sold by the Selling Shareholder.

Our Depositary Shares are
currently listed on The NASDAQ Capital Market under the symbol “BDRX.”

<div align='center'>EXPENSES OF THE OFFERING</div>

The following table sets
forth the expenses payable by us in connection with the sale and distribution of the securities being registered hereby. All amounts shown,
other than the SEC registration fee, are estimates:

| SEC registration fee         | $ | 23,304 |
| Depositary fees and expenses |   |      * |
| Printing and engraving       |   |      * |
| Accounting services          |   |      * |
| Legal fees and expenses      |   |      * |
| Miscellaneous                |   |      * |
| Total                        | $ |      * |

_______________

*These fees are calculated based on the securities offered and number
of issuances and accordingly cannot be defined at this time.

<div align='center'>LEGAL MATTERS</div>

Certain legal matters in connection
with the validity of the securities offered hereby will passed upon for us by Brown Rudnick LLP, London, United Kingdom. Certain other matters of U.S. federal law will be passed upon for us by Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C., Boston, Massachusetts.

| 76 |

<div align='center'>EXPERTS</div>

The financial statements as
of December 31, 2024, and for the year then ended, incorporated by reference into this prospectus and in the registration statement have
been so incorporated in reliance on a report PKF Littlejohn LLP, an independent registered accounting firm, given on authority of said
firm as experts in auditing and accounting. The report on the financial statements for the year ended December 31, 2024 contains an explanatory
paragraph regarding our ability to continue as a going concern.

PKF Littlejohn LLP, London,
United Kingdom, is a member of the Institute of Chartered Accountants